These comprised data led to the currently enrolling FIDES-01 trial, a phase 2 open-label, single-arm trial testing 300mg daily of derazantinib for patients with ICCA that harbor FGFR2-fusions, but also mutations or amplifications, as it was recently shown that derazantinib has similar efficacy in these cases (32). The gene discussed is FGFR2; the disease is infantile convulsions and choreoathetosis.